Sangjun Lee

Sangjun Lee

Speaker : Byung Gon Kim (Associate Professor, Ajou University School of Medicine) 

Date : 2011-12-14

Location : Room 108Pharmacy Hall, Dankook University

Abstract : Stem cell transplantation holds promise to promote anatomical repair and functional recovery after traumatic or ischemic injuries in CNS. Harnessing stem cells with therapeutic genes of interest is regarded as an attractive approach to augment therapeutic benefits of stem cell grafts. The advantage of stem cell-mediated gene transfer is the engraftibility of stem cells that can ensure a long-term and stable expression of therapeutic genes. In addition, stem cell-gene interaction may synergistically amplify therapeutic benefits. Delivery of classical neurotrophic factor genes provided neuroprotective and pro-regenerative effects in various injury models. Some studies employed therapeutic genes targeting post-injury microenvironment to support endogenous repair. Recent trials of stem cell-mediated transfer of nonclassical growth factors showed relatively novel biological effects. Combinatorial strategies seem to have the potential to improve therapeutic efficacy. Future development of induced pluripotent stem cells and novel scaffolding biomaterials will greatly expedite the advances of the ex vivo gene therapy to treat CNS injury. Before moving to the clinical stage, rigorous preclinical evaluation to identify an optimal gene or gene combination in different injury settings needs to be performed. Improving the safety of viral vectors will be a critical prerequisite for the clinical translation.

Speaker : Myung Soo Cho (책임연구원, 제일약품㈜ 중앙개발연구소 신약연구실) 

Date : 2011-12-20

Location : Room 108Pharmacy Hall, Dankook University

Abstract : 21세기에 들어 휴먼 제놈이 밝혀지면서 생물학에서는 genomics, proteomics등과 같은 생체 물질의 전체적인 변화를 보고자 하는 연구가 가능해졌으며 이러한 연구는 새로운 의약품 개발과 정확한 진단과 치료로 이어질 수 있는 의료기술의 혁신으로 이어지고 있습니다. 

바이오 의약품은 초창기 단백질 hormone이나 cytokine류로서 환자에게 부족한 단백질을 추가 하는 방향 이였지만 지금은 항체의약품과 같이 체내에서 악영향을 미치는 활성 성분을 억제하는 기능을 갖는 의약품의 시장이 크게 증가 되고 있으며 줄기세포 치료기술도 발전하고 있습니다. 그래서 바이오 의약품은 기존 의약품의 주류를 이루었던 정밀화학의약품을 대체하고 있는데 그 강점은 적은 부작용과 정확한 치료효과입니다. 이러한 강점은 맞춤형 의약품으로 발전해 나아가는데 이러한 진척에 선행되어야 하는 것이 해당 질병의 구체적인 원인이나 상태를 알려주는 바이오마커의 발굴입니다.     

본 세미나에는 프로테옴믹스를 이용한 바이오마커의 발굴과 그 기법들 그리고 이를 응용한 의약품개발을 함께 생각하고자 합니다

Speaker : Lim, Kook Jin, Ph.D. ㈜프로테옴텍 대표이사

Date : 2012-01-10

Location : Room 106Pharmacy Hall, Dankook University

Abstract : 21세기에 들어 휴먼 제놈이 밝혀지면서 생물학에서는 genomics, proteomics등과 같은 생체 물질의 전체적인 변화를 보고자 하는 연구가 가능해졌으며 이러한 연구는 새로운 의약품 개발과 정확한 진단과 치료로 이어질 수 있는 의료기술의 혁신으로 이어지고 있습니다. 

바이오 의약품은 초창기 단백질 hormone이나 cytokine류로서 환자에게 부족한 단백질을 추가 하는 방향 이였지만 지금은 항체의약품과 같이 체내에서 악영향을 미치는 활성 성분을 억제하는 기능을 갖는 의약품의 시장이 크게 증가 되고 있으며 줄기세포 치료기술도 발전하고 있습니다. 그래서 바이오 의약품은 기존 의약품의 주류를 이루었던 정밀화학의약품을 대체하고 있는데 그 강점은 적은 부작용과 정확한 치료효과입니다. 이러한 강점은 맞춤형 의약품으로 발전해 나아가는데 이러한 진척에 선행되어야 하는 것이 해당 질병의 구체적인 원인이나 상태를 알려주는 바이오마커의 발굴입니다.     

본 세미나에는 프로테옴믹스를 이용한 바이오마커의 발굴과 그 기법들 그리고 이를 응용한 의약품개발을 함께 생각하고자 합니다

Speaker : Hong, Kwan Soo (Principal Researcher, Korea Basic Science Institute) 

Date : 2012-01-17

Location : Room 103-01Pharmacy Hall, Dankook University

Abstract : Magnetic resonance imaging (MRI) is a widely used clinical diagnostic tool because it is non-invasive, provides contrast among soft tissues at high spatial resolution. Conventional MRI focuses almost exclusively on visualizing anatomy and has no specificity for any particular cell type. The 'probe' used in conventional MRI is the proton (1H) in mobile water molecules. New classes of exogenous MRI probes or reagents are needed to facilitate cell-specific imaging in living subjects. Elucidating the trafficking pathways of cells (immune and stem cells) in vivo, together with their migratory properties in relation to their differentiation and activation status, is useful for understanding how the immune system interacts with the related diseases. Methods based on tissue sampling to monitor immune responses are inadequate for repeatedly characterizing the responses of the immune system in different organs. A solution to this problem might come from molecular and cellular imaging - a branch of biomedical sciences that combines biotechnology and imaging methods to characterize, in vivo, the molecular and cellular processes involved in normal and pathologic states. The targeted cells are labeled with magnetic nano-particle-based multimodal contrast agents (CAs) in vivo or in vitro, which gives contrast where the labelled cells are. The CA-mediated in vivo molecular/cellular imaging provides new insights into the biology of cell trafficking and migration, in particular, the recruitment of immune cells into immune disease sites, and the longitudinal tracing of the transplanted cells homing to the disease sites.

Speaker : 박희곤 교수

Date : 2012-01-19

Location : Room 108Pharmacy Hall, Dankook University

Speaker : Dong Wook Han, Ph.D. (건국대학교/Max Planck Institute for Molecular Biomedicine)

Date : 2012-03-27

Location : Room 106Pharmacy Hall, Dankook University

Abstract : Recent studies have shown that defined sets of transcription factors can directly reprogram differentiated somatic cells to a different differntiatied cell type without passing through a pluripotent state, but the restricted proliferative and lineage potential of the resulting cells limits the scope of their potential application. Here we show that a combination of transcription factors(Brn4/Pou3f4, Sox2, Klf4, c-Myc, plus E47/Tcf3) induces mouse fibroblasts to directly acquire a neural stem cell identity-which we term as induced neural stem cells(iNSCs). Direct reprogramming of fibroblasts into iNSCs is a gradual process in which the donor transcriptional program is silenced over time. iNSCs exhibit cell morphology, gene expression, epigenetic features, differentiation potential, and self-renewing capacity, as well as in vitro and in vivo functionality similar to those of wild-type NSCs. We conclude that differentiated cells can be reprogrammed directly into specific somatic stem cell types by defined sets of specific transcription factors.

Tuesday, 21 July 2015 10:10

31 - Microfluidic for Tissue Engineering

Speaker : Jeongyun Kim, Ph.D.(Research Professor, Department of Biomedical Engineering, College of Health Science, Korea University)

Date : 2012-06-08

Location : Room 106Pharmacy Hall, Dankook University

Abstract : Microfluidic 은 1980년대에 잉크젯 프린터로 세상에 알려지기 시작하였으며, 90년대들어 Harvard University 화학과 교수인 George Whiteside에 의해 PDMS라는 polymer를 이용하면서 Biology 에 적용되기 시작하였으며, 오늘날에는 전통적인 생물학적 실험방법으로 실현이 불가능했던 부분들을 microfluidic chip에서 실현함으로써 생물학 발전에 많은 기여를 하고 있다.

이에 본 발표에서는 microfluidic이 biology에 어떻게 적용이 되어 왔으며, 향후 어떤 방향으로 전개되어 갈지에 대해 아래와 같이 3가지 부분에 대해 설명하고자 한다.

1. Lab-on-a-Chip구현을 위한 Microfluidic의 물리적 현상 

2. Tissue Engineering을 위한 Microfluidic의 활용 예(발표자의 연구 결과 포함) 

3. 단국대학교에서 진행중인 연구와 관련한 몇가지 실험적 제안 

Speaker : Takuya Matsumoto, Ph.D. (Professor & Chair, Department of Biomaterials, Graduate School of Medicine, Dentistry and  Pharmaceutical Sciences, Okayama University)

Date : 2012-07-31

Location : Room 107Pharmacy Hall, Dankook University

Abstract : In vitro fabricated biological tissue would be an ultimate implantable material for tissue regeneration. It also would be valuable tools for screening multiple drugs at a time. Thanks to the advancement of tissue engineering studies in the last few decades, researchers now develop several technique to manipulate cells for in vitro tissue synthesis. In this talk, I would like to introduce our materials and technique for in vitro cell and tissue manipulation for the future in vitro tissue synthesis.

Thursday, 23 July 2015 10:10

33 - Strategies in Designing Efficient

Speaker : Yoon Shin Park, Ph.D.  (Research Professor, Ewha Womans University Medical School) 

Date : 2012-08-07

Location : Room 106Pharmacy Hall, Dankook University

Abstract : Cell permeable peptides (CPPs) are known for their versatility in carrying macro- or supramolecules through the cell membrane barriers that challenge the conventional drug-delivery approaches. The CPPs are capable of transporting their cargos, often linked by a covalent bond, into almost all cell types. Among such CPPs, we previously reported a new CPP, low molecular weight protamine (LMWP) peptide (VSRRRRRRGGRRRR) developed by enzymatic digestion of protamine (an FDA-approved drug), as a potent yet nontoxic CPP or membrane translocalization carrier. Both in vitro and animal investigations demonstrated that, via covalent or electrostatic conjugation, LMWP was able to transduce its attached protein, gene or carrier cargo into various types of cells. The LMWP offers distinct advantages. First, LMWP is as potent as the virus-derived TAT peptide, the most-studied CPP to date, in mediating cellular translocation of the attached cargos. Secondly, unlike other CPPs, the toxicity profile of LMWP has already been thoroughly established. LMWP was shown to be nonimmunogenic, and its use in dogs did not elicit acute toxic responses. Lastly, while other CPPs must be chemically synthesized, LMWP can be produced in mass quantities direct from native protamine with limited processing time and cost. More recently, it was shown that cell translocation mediated by LMWP does not cause any perturbation or damage to the cell membrane. Therefore, we suggest that LMWP can be used as a tool to aid intracellular delivery of drugs into target cells.

Speaker : Chan Hum Park, M.D(School of Medicine, Hallym University)

Date : 2012-09-14

Location : Room 106Pharmacy Hall, Dankook University

Abstract : Silk fibroin of silkworms has been widely studied as biomaterials. In our institute, we fabricated various types of biomaterials using silk fibroin. Silk patch presented no cytotoxicity in L929 cells and rat tissue. We investigated the degradation behavior of silk patch in vitro and in vivo, and the effects of repairing large tympanic membrane (TM) perforations in rats with a thin silk patch compared with the commonly used paper patch. The results indicated that silk patch is a good biocompatible and has a long degradation time as biomaterials. Also, we showed that silk patch treatment accelerates wound healing and shortens TM perforation closure time. 

 Next, we fabricated silk fibroin (SF) nanofiber mats by electrospinning to develop biodegradable electrospun dermal scaffolds to replace donor human dermis or bovine collagen for 3D skin reconstruction for future clinical use. We prepared SF nanofiber mats that were recrystallized in different ways. These mats were fabricated by electrospinning with ethanol/propanol mixtures of various blend ratios, and their biodegradabilities in vitro and in vivo were evaluated using rats. As a result, we can suggest an established method to modulate the degradability of SF nanofibrous materials based on long-term (12 months) observations. In particular, we elucidated how the SF nanofibers are degraded and incorporated with surrounding tissue by observation of fluorescein isothiocyanate (FITC)–labeled SF nanofiber in vivo. Also we showed that SF nanofiber mats have a good biocompatibity and effect for wound healing. Our findings suggest that SF nanofiber mats could be materials to be utilized as dermal substitute for tissue engineering.

페이지 7 / 전체 11